Facebook
Twitter
Telegram
Report an ErrorPhaseBio Pharmaceuticals Balance Sheet 2011-2024 | PHAS
Annual Balance Sheet PhaseBio Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-39.4 M | -16 M | -59.3 M | -53.5 M | 2.08 M | -3.72 M | - | - | - | - | - |
Long Term Debt |
1.36 M | 6.77 M | 12.3 M | 7.5 M | 2.62 M | - | - | - | - | - | - |
Long Term Debt Current |
1 M | 459 K | 265 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | 60.6 M | 14 M | 7.52 M | 93.9 M | 90.5 M | - | - | - | - | - |
Total Current Liabilities |
27.9 M | 15 M | 8.48 M | 4.58 M | - | - | - | - | - | - | - |
Total Liabilities |
154 M | 75.6 M | 22.5 M | 12.1 M | 112 M | 91.3 M | - | - | - | - | - |
Deferred Revenue |
1.55 M | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-392 M | -261 M | -162 M | -123 M | -99.1 M | -88.8 M | - | - | - | - | - |
Total Assets |
60.5 M | 50.4 M | 82.5 M | 63 M | 14.1 M | 4.12 M | - | - | - | - | - |
Cash and Cash Equivalents |
41.8 M | 28.1 M | 74 M | 61 M | 13.4 M | - | - | - | - | - | - |
Book Value |
-93 M | -25.2 M | 60 M | 50.9 M | -97.4 M | -87.2 M | - | - | - | - | - |
Total Shareholders Equity |
-93 M | -25.2 M | 60 M | 50.9 M | -97.4 M | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet PhaseBio Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | 1.36 M | 2.72 M | 4.07 M | 5.42 M | 6.77 M | 6.77 M | 6.77 M | 6.77 M | 12.3 M | 12.3 M | 12.3 M | 12.3 M | 7.5 M | 7.5 M | 7.5 M | 7.5 M | 2.62 M | 2.62 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | 140 M | 141 M | 154 M | 128 M | 120 M | 92.4 M | 75.6 M | 75.6 M | 75.6 M | 75.6 M | 22.5 M | 22.5 M | 22.5 M | 22.5 M | 12.1 M | 12.1 M | 12.1 M | 12.1 M | 21.9 M | 21.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | 1.4 M | 1.59 M | 1.55 M | 1.41 M | 1.42 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
- | - | -420 M | -403 M | -392 M | -349 M | -317 M | -288 M | -261 M | -261 M | -261 M | -261 M | -162 M | -162 M | -162 M | -162 M | -123 M | -123 M | -123 M | -123 M | -99.1 M | -99.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
- | - | 22.2 M | 38.7 M | 60.5 M | 77.7 M | 101 M | 101 M | 50.4 M | 50.4 M | 50.4 M | 50.4 M | 82.5 M | 82.5 M | 82.5 M | 82.5 M | 63 M | 63 M | 63 M | 63 M | 14.1 M | 14.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
- | - | 7.8 M | 18.7 M | 41.8 M | 56.4 M | 64.5 M | 77 M | 28.1 M | 28.1 M | 28.1 M | 28.1 M | 74 M | 74 M | 74 M | 74 M | 61 M | 61 M | 61 M | 61 M | 13.4 M | 13.4 M | - | - | 3.72 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
- | - | -117 M | -102 M | -93 M | -50.3 M | -19.2 M | 8.41 M | -25.2 M | -25.2 M | -25.2 M | -25.2 M | 60 M | 60 M | 60 M | 60 M | 50.9 M | 50.9 M | 50.9 M | 50.9 M | -7.78 M | -7.78 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
- | - | -117 M | -102 M | -93 M | -50.3 M | -19.2 M | 8.41 M | -25.2 M | -25.2 M | -25.2 M | -25.2 M | 60 M | 60 M | 60 M | 60 M | 50.9 M | 50.9 M | 50.9 M | 50.9 M | -97.4 M | -97.4 M | - | - | -87.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency